TUTCRIS - Tampereen teknillinen yliopisto

TUTCRIS

Urinary Polyamines as Biomarkers for Ovarian Cancer

Tutkimustuotosvertaisarvioitu

Standard

Urinary Polyamines as Biomarkers for Ovarian Cancer. / Niemi, Riikka; Roine, Antti; Häkkinen, Merja; Kumpulainen, Pekka; Keinänen, Tuomo; Vepsäläinen, Jouko; Lehtimäki, Terho; Oksala, Niku; Mäenpää, Johanna.

julkaisussa: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vuosikerta 27, Nro 7, 09.2017, s. 1360-1366.

Tutkimustuotosvertaisarvioitu

Harvard

Niemi, R, Roine, A, Häkkinen, M, Kumpulainen, P, Keinänen, T, Vepsäläinen, J, Lehtimäki, T, Oksala, N & Mäenpää, J 2017, 'Urinary Polyamines as Biomarkers for Ovarian Cancer', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vuosikerta. 27, Nro 7, Sivut 1360-1366. https://doi.org/10.1097/IGC.0000000000001031

APA

Niemi, R., Roine, A., Häkkinen, M., Kumpulainen, P., Keinänen, T., Vepsäläinen, J., ... Mäenpää, J. (2017). Urinary Polyamines as Biomarkers for Ovarian Cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 27(7), 1360-1366. https://doi.org/10.1097/IGC.0000000000001031

Vancouver

Niemi R, Roine A, Häkkinen M, Kumpulainen P, Keinänen T, Vepsäläinen J et al. Urinary Polyamines as Biomarkers for Ovarian Cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2017 syys;27(7):1360-1366. https://doi.org/10.1097/IGC.0000000000001031

Author

Niemi, Riikka ; Roine, Antti ; Häkkinen, Merja ; Kumpulainen, Pekka ; Keinänen, Tuomo ; Vepsäläinen, Jouko ; Lehtimäki, Terho ; Oksala, Niku ; Mäenpää, Johanna. / Urinary Polyamines as Biomarkers for Ovarian Cancer. Julkaisussa: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2017 ; Vuosikerta 27, Nro 7. Sivut 1360-1366.

Bibtex - Lataa

@article{db6adae3b9f64c11a74c87d2193ec8c8,
title = "Urinary Polyamines as Biomarkers for Ovarian Cancer",
abstract = "OBJECTIVES:Elevated concentrations of polyamines have been found in urine of patients with malignant tumors, including ovarian cancer. Previous research has suffered from poorly standardized detection methods. Our liquid chromatography-tandem mass spectrometry (LC-MS/MS) method is capable of simultaneous standardized analysis of most known polyamines. Liquid chromatography-tandem mass spectrometry has not previously been used in the differential diagnostics of ovarian tumors in postmenopausal women.MATERIALS AND METHODS:In this prospective study, postmenopausal women (n = 71) presenting with an adnexal mass and, as controls, women with genital prolapse or urinary incontinence scheduled for surgery (n = 22) were recruited in the study. For analysis of the polyamines, a morning urine sample was obtained before surgery. Preoperative serum CA125 concentrations were determined in the study group.RESULTS:Twenty-three women with benign and 37 with malignant ovarian tumors were eligible. Of all analyzed polyamines, only urinary N,N-diacetylspermine showed statistically significant differences between all groups except controls versus benign tumors. N,N-diacetylspermine was elevated in malignant versus benign tumors (P < 0.001), in high-grade versus low malignant potential tumors (P < 0.001), in stage III to IV versus stage I to II cancers (P < 0.001), and even in early-stage cancer (stage I-II) versus benign tumors (P = 0.017). N,N-diacetylspermine had better sensitivity (86.5{\%}) but lower specificity (65.2{\%}) for distinguishing benign and malignant ovarian tumors than CA125 with a cut-off value of 35 kU/L (sensitivity, 75.7{\%}; specificity, 69.6{\%}).CONCLUSIONS:Urinary N,N-diacetylspermine seems to be able to distinguish benign and malignant ovarian tumors as well as early and advanced stage, and low malignant potential and high-grade ovarian cancers from each other, respectively.",
author = "Riikka Niemi and Antti Roine and Merja H{\"a}kkinen and Pekka Kumpulainen and Tuomo Kein{\"a}nen and Jouko Veps{\"a}l{\"a}inen and Terho Lehtim{\"a}ki and Niku Oksala and Johanna M{\"a}enp{\"a}{\"a}",
year = "2017",
month = "9",
doi = "10.1097/IGC.0000000000001031",
language = "English",
volume = "27",
pages = "1360--1366",
journal = "INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER",
issn = "1048-891X",
publisher = "Lippincott, Williams & Wilkins",
number = "7",

}

RIS (suitable for import to EndNote) - Lataa

TY - JOUR

T1 - Urinary Polyamines as Biomarkers for Ovarian Cancer

AU - Niemi, Riikka

AU - Roine, Antti

AU - Häkkinen, Merja

AU - Kumpulainen, Pekka

AU - Keinänen, Tuomo

AU - Vepsäläinen, Jouko

AU - Lehtimäki, Terho

AU - Oksala, Niku

AU - Mäenpää, Johanna

PY - 2017/9

Y1 - 2017/9

N2 - OBJECTIVES:Elevated concentrations of polyamines have been found in urine of patients with malignant tumors, including ovarian cancer. Previous research has suffered from poorly standardized detection methods. Our liquid chromatography-tandem mass spectrometry (LC-MS/MS) method is capable of simultaneous standardized analysis of most known polyamines. Liquid chromatography-tandem mass spectrometry has not previously been used in the differential diagnostics of ovarian tumors in postmenopausal women.MATERIALS AND METHODS:In this prospective study, postmenopausal women (n = 71) presenting with an adnexal mass and, as controls, women with genital prolapse or urinary incontinence scheduled for surgery (n = 22) were recruited in the study. For analysis of the polyamines, a morning urine sample was obtained before surgery. Preoperative serum CA125 concentrations were determined in the study group.RESULTS:Twenty-three women with benign and 37 with malignant ovarian tumors were eligible. Of all analyzed polyamines, only urinary N,N-diacetylspermine showed statistically significant differences between all groups except controls versus benign tumors. N,N-diacetylspermine was elevated in malignant versus benign tumors (P < 0.001), in high-grade versus low malignant potential tumors (P < 0.001), in stage III to IV versus stage I to II cancers (P < 0.001), and even in early-stage cancer (stage I-II) versus benign tumors (P = 0.017). N,N-diacetylspermine had better sensitivity (86.5%) but lower specificity (65.2%) for distinguishing benign and malignant ovarian tumors than CA125 with a cut-off value of 35 kU/L (sensitivity, 75.7%; specificity, 69.6%).CONCLUSIONS:Urinary N,N-diacetylspermine seems to be able to distinguish benign and malignant ovarian tumors as well as early and advanced stage, and low malignant potential and high-grade ovarian cancers from each other, respectively.

AB - OBJECTIVES:Elevated concentrations of polyamines have been found in urine of patients with malignant tumors, including ovarian cancer. Previous research has suffered from poorly standardized detection methods. Our liquid chromatography-tandem mass spectrometry (LC-MS/MS) method is capable of simultaneous standardized analysis of most known polyamines. Liquid chromatography-tandem mass spectrometry has not previously been used in the differential diagnostics of ovarian tumors in postmenopausal women.MATERIALS AND METHODS:In this prospective study, postmenopausal women (n = 71) presenting with an adnexal mass and, as controls, women with genital prolapse or urinary incontinence scheduled for surgery (n = 22) were recruited in the study. For analysis of the polyamines, a morning urine sample was obtained before surgery. Preoperative serum CA125 concentrations were determined in the study group.RESULTS:Twenty-three women with benign and 37 with malignant ovarian tumors were eligible. Of all analyzed polyamines, only urinary N,N-diacetylspermine showed statistically significant differences between all groups except controls versus benign tumors. N,N-diacetylspermine was elevated in malignant versus benign tumors (P < 0.001), in high-grade versus low malignant potential tumors (P < 0.001), in stage III to IV versus stage I to II cancers (P < 0.001), and even in early-stage cancer (stage I-II) versus benign tumors (P = 0.017). N,N-diacetylspermine had better sensitivity (86.5%) but lower specificity (65.2%) for distinguishing benign and malignant ovarian tumors than CA125 with a cut-off value of 35 kU/L (sensitivity, 75.7%; specificity, 69.6%).CONCLUSIONS:Urinary N,N-diacetylspermine seems to be able to distinguish benign and malignant ovarian tumors as well as early and advanced stage, and low malignant potential and high-grade ovarian cancers from each other, respectively.

U2 - 10.1097/IGC.0000000000001031

DO - 10.1097/IGC.0000000000001031

M3 - Article

VL - 27

SP - 1360

EP - 1366

JO - INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

JF - INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

SN - 1048-891X

IS - 7

ER -